Antoxerene
Small molecule drug discovery targeting aging pathways.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
$1.5m | Seed | ||
| Total Funding | 000k | ||
Related Content
Antoxerene, Inc. is a pharmaceutical company founded in 2016 that develops small molecule drugs aimed at the biological pathways of aging. Headquartered in LaFayette, New York, the company operates as a portfolio company and affiliate of Ichor Therapeutics. The leadership team includes individuals such as CEO Kelsey Moody and COO Aaron Wolfe.
The firm's core focus is on discovering and developing novel compounds to selectively destroy toxic senescent cells—cells that have stopped dividing and contribute to age-related diseases. Antoxerene utilizes a proprietary next-generation screening technology to study protein-protein interactions that are crucial for the survival of these harmful cells. This approach allows them to identify potential drug candidates that can restore tissue function. A significant area of their research involves the p53/FOXO4 pathway, which is implicated in cellular aging, and the p53/MDM2 pathway, a known oncology target. The company developed a proprietary protein tagging system to produce and express the p53 protein in large quantities, enabling high-throughput screening for new therapeutic compounds.
Antoxerene's business model involves identifying promising drug leads and advancing them through pre-clinical development, often in partnership with other entities. In 2018, the company launched a joint venture named FoxBio, Inc. with Juvenescence Limited to develop its portfolio of small molecules that target senescent cells. This partnership was supported by a $10 million equity financing deal from Juvenescence to leverage its drug development expertise. Prior to this, Antoxerene had secured a $1.5 million seed round with participation from investors like Michael Greve's Kizoo Technology Capital and the SENS Research Foundation.
Keywords: senolytics, small molecule drugs, drug discovery, aging pathways, cellular senescence, protein-protein interactions, p53 pathway, rejuvenation biotechnology, preclinical research, age-associated diseases, high-throughput screening, FOXO4, senescent cells, gerontology, biopharmaceutical, oncology target, tissue restoration, drug development, Ichor Therapeutics, FoxBio
